Results 201 to 210 of about 410,880 (314)

Results of the feasibility study of clinical trials of the new cancer treatment technology Karanahan for patients with advanced breast cancer. [PDF]

Transl Cancer Res
Proskurina AS, Markina VA, Ruzanova VS, Ritter GS, Dolgova EV, Kirikovich SS, Levites EV, Efremov YR, Vereschagin EI, Leplina OY, Ostanin AA, Chernykh ER, Kolchanov NA, Sidorov SV, Bogachev SS.   +14 more
europepmc   +1 more source

The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging

Advanced Science, EarlyView.
This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma, Rui Guo, Dongfeng Niu, Yufei Song, Zhenyao Zhang, Xiangxi Meng, Lili Mao, Haifeng Huang, Hua Zhu, Zhi Yang, Teli Liu   +10 more
wiley   +1 more source

Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study. [PDF]

Eur J Breast Health
Ferreira RQ, Monteiro CB, Dias AC, Abreu F, Darmits B, Oura MJ, Ângelo I, Cabral J, Figueiredo A, Ferreira R, Alpuim Costa D, Marques MT, Pina-Cabral T, Araújo F, Bento S, Fernandes CL, Santiago M, Silva B, Montenegro MA, Simão DC, Fernandes L, Oliveira SD.   +21 more
europepmc   +1 more source

S100A14 in Tumor‐Derived EVs Targets PIAS3 to Reprogram Astrocytes and Induce Immunosuppressive Microenvironment Promoting Brain Metastasis and Germacrone Reversal Effect

Advanced Science, EarlyView.
This study identifies S100A14 in tumor‐derived exosomes as a key driver of brain metastasis. S100A14 targets PIAS3 in astrocytes, activating STAT3 signaling and promoting immunosuppressive MDSCs recruitment via chemokine secretion. Germacrone, a natural compound, binds S100A14 to disrupt this axis, effectively inhibiting brain metastasis with low ...
Qian Feng, Xia Yang, Lin An, Xue‐Yu Wang, Ming‐Rui Wang, Zhuo‐Hong Cai, Cai‐Jun Xie, Li‐Jun Qiao, You‐Bi Shen, Xi‐Min Liang, Rong Zhang, Cai‐Yan Wang, Zhong‐Qiu Liu, Rong‐Rong Zhang   +13 more
wiley   +1 more source

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry. [PDF]

NPJ Breast Cancer
Hörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, Amann N, Cieslik JP, Tretschock LM, Dannehl D, Deutsch TM, Dimpfl M, Ehlert M, Eichstädt K, Englisch A, Köpke MB, Krückel A, Link T, Müller A, Reinhardt K, Roth J, Schäffler H, Sych L, Tauber N, Tegeler CM, Wichmann C, Banys-Paluchowski M, Princk H, Rody A, Brucker SY, Ditsch N, Ettl J, Fehm T, Hack CC, Hadji P, Hein A, Janni WW, Kolberg HC, Lüftner D, Lux MP, Müller V, Taran FA, Tesch H, Wallwiener D, Marmé F, Seitz S, Belleville E, Michel LL, Wallwiener M, Fasching PA, Schneeweiss A, Maurer C.   +52 more
europepmc   +1 more source

Amuc_1473 Links Gut Microbes to Skeletal Homeostasis and Counteracts Multifactorial Osteoporosis

Advanced Science, EarlyView.
Amuc_1473, a previously uncharacterized protein enriched in Akkermansia muciniphila‐derived extracellular vesicles, is identified as a gut–bone messenger that promotes osteogenesis and inhibits osteoclastogenesis by engaging transcriptional and translational regulators in bone cells.
Shan‐Shan Rao, Hai‐Jin Zeng, Zun Wang, Chun‐Gu Hong, Yi‐Juan Tan, Yan‐Xin Duan, Jing‐Yao Luo, Ming‐Jie Luo, Yi‐Wei Liu, Xin Wang, Yi Luo, Teng‐Fei Wan, Yong Zhou, Zheng‐Guang Wang, Guo‐Wen Hu, Hao Yin, Xin‐Yue Hu, Zhen‐Xing Wang, Ze‐Hui He, Si‐Yi Cheng, Wei Du, Zhe Guan, Hai‐Li Lang, Hong‐Ji Liu, Jia Cao, Peng Chen, Jiang‐Hua Liu, Hui Xie, Chun‐Yuan Chen   +28 more
wiley   +1 more source

Circulating DNA tumor fraction as a biomarker for advanced breast cancer. [PDF]

Front Oncol
Cybulla E, Stover DG.
europepmc   +1 more source

Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma

Advanced Science, EarlyView.
MDM2 dependency in pediatric sarcomas is driven by a novel p53‐independent oncogenic cistrome alongside canonical p53 pathway suppression. This study introduces MDM2‐recruiting transcriptional and epigenetic machinery degraders (MDM2‐TEMADs) as a novel precision oncology modality.
Jiawei Zhou, Xian Guan, Nan Li, Ying Zhang, Long Xie, Xingze Huang, Zhipeng Zhu, Zhuolin Ren, Xiaoyan Yu, Hanjun Guo, Yuanfang Wu, Lin Ma, Suya Zheng, Jingyao Zhang, Jiyang Liu, Victor Kuanmin Lee, Wenhao Chen, H. Phillip Koeffler, Jinhu Wang, Xin Han, Ye Chen, Liang Xu   +21 more
wiley   +1 more source

Early Detection and Inhibition of Post‐Surgical Cancer Recurrence by Synthetic Extracellular Vesicles

Advanced Science, EarlyView.
An implantable hydrogel is designed to hold gene transfection agents engineered to turn early recurrent tumor cells into generators of synthetic EVs. These synthetic EVs can express engineered miR‐26a (E‐miR‐26a) for highly sensitive detection and PD‐1 (a PD‐L1‐blocking agent) for therapeutic intervention, thereby enabling early detection and ...
Junli Zhang, Wenjia Chang, Ruolin Hu, Peiyan Su, Qin Zhou, Yanan Li, Zhenzhong Zhang, Kaixiang Zhang   +7 more
wiley   +1 more source

Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project. [PDF]

ESMO Open
Sánchez-Bayona R, de Nicolás-Hernández J, Saura C, Gion M, Cejalvo JM, Llabrés E, Cortés J, Falcón A, Pernas S, López de Sa A, Vidal M, Hinojo C, Curiel T, Cruz J, Martínez V, Cantos B, Echarri MJ, Gallegos I, Bueno C, Vargas AM, Escrivá-de-Romaní S, Fullana B, Cobos MA, Arenas A, Joval-Ramentol L, Ortiz P, Pascual T, Valdivia C, Villacampa G, Ciruelos E, Rodriguez-Antona C.   +30 more
europepmc   +1 more source